Antithrombotic Therapy in High Bleeding Risk, Part II
JACC: Cardiovascular Interventions · 2024
DOI: 10.1016/j.jcin.2024.09.011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Mattia Galli und 16 weiteren Autor:innen. Beteiligte Einrichtung: Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy. Hauptthemen laut MEDLINE: Hemorrhage, Fibrinolytic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Abstract (Originalsprache)
Over the past decades, there have been great advancements in the antithrombotic management of patients undergoing percutaneous interventions, but most of the available evidence derives from studies conducted in the setting of cardiac interventions. Antithrombotic treatment regimens used in patients undergoing percutaneous cardiac interventions, in particular coronary, are frequently extrapolated to patients undergoing noncardiac interventions. However, the differences in risk profile of the population treated and the types of interventions performed may translate into differences is the safety and efficacy associated with antithrombotic therapy. Noncardiac percutaneous interventions are commonly performed in patients at high bleeding risk, which may indeed impact outcomes, hence underscoring the importance of risk stratification to guide clinical decision-making processes. In this review, we appraise the available evidence on antithrombotic therapy in high-bleeding-risk patients undergoing noncardiac percutaneous interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
- Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Caserta, Italy; Division of Clinical Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy.
- Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
- Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. Electronic address: rossella.marcucci@unifi.it.
- Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Catholic University Medical School, Rome, Italy.
Zitieren
APA
Galli, M., Gragnano, F., Berteotti, M., Marcucci, R., Gargiulo, G., Calabrò, P., Terracciano, F., Andreotti, F., Patti, G., De Caterina, R., Capodanno, D., Valgimigli, M., Mehran, R., Perrone Filardi, P., Cirillo, P., Angiolillo, D. J., & Working Group of Thrombosis of the Italian Society of Cardiology (2024). Antithrombotic Therapy in High Bleeding Risk, Part II. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.09.011
Vancouver
Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, et al. Antithrombotic Therapy in High Bleeding Risk, Part II. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.09.011
BibTeX
@article{Galli2024,
author = {Galli, Mattia and Gragnano, Felice and Berteotti, Martina and Marcucci, Rossella and Gargiulo, Giuseppe and Calabrò, Paolo and Terracciano, Fabrizia and Andreotti, Felicita and Patti, Giuseppe and De Caterina, Raffaele and Capodanno, Davide and Valgimigli, Marco and Mehran, Roxana and Perrone Filardi, Pasquale and Cirillo, Plinio and Angiolillo, Dominick J and Working Group of Thrombosis of the Italian Society of Cardiology, Working Group of Thrombosis of the Italian Society of Cardiology},
title = {Antithrombotic Therapy in High Bleeding Risk, Part II},
journal = {JACC: Cardiovascular Interventions},
year = {2024},
doi = {10.1016/j.jcin.2024.09.011}
}
EUVIMED